KRAS and neoplasm: For example, in colorectal cancer (CRC), tumor-derived lanosterol can be taken up by CD8+ T cells, where it suppresses the mevalonate pathway and reduces prenylation and activity of KRAS proto-oncogene, GTPase (KRAS), ultimately promoting T cell apoptosis and impairing their antitumor function.